Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Hemoglobinopathies, Sickle Cell Disease, Thalassemia
About this trial
This is an interventional treatment trial for Hemoglobinopathies focused on measuring Hemoglobinopathies, Sickle cell anemia, sickle cell-hemoglobin C disease, sickle cell-B-thalassemia, transfusion-dependant thalassemia, allogeneic transplant, nonmyeloablative transplant, Stem cell transfusion, graft vs. host disease
Eligibility Criteria
Inclusion Criteria: Patients with sickle cell disease should have one or more of the following: acute chest syndrome requiring hospitalization; nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours; recurrent caso-occlusive pain or recurrent priapism; sickle neuropathy; bilateral proliferative retinopathy and major visual impairment of at least one eye; osteonecrosis of multiple joints; transfusion dependence; vaso-occlusive. Patients with thalassemia should have one or more of the following: transfusion dependence; iron overload; presence of 2 or more alloantibodies against red cell antigens. Exclusion Criteria: Pregnancy Acute hepatitis Cardiac ejection fraction < 30% Severe renal impairment Severe residual functional neurologic impairment Evidence of HIV infection
Sites / Locations
- Winship Cancer Institute-Emory University
- Feist-Weiller Cancer Center-LSU
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- Ohio State University College of Medicine